Stay updated on Pembrolizumab Combo vs Alone in Stage III Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo vs Alone in Stage III Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab Combo vs Alone in Stage III Melanoma Clinical Trial page
- Check4 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content or functionality of the page.SummaryDifference0.1%
- Check47 days agoChange DetectedThe page has been updated to include new investigational treatments for melanoma, specifically the addition of MK-4830 and Favezelimab + Pembrolizumab, while significant details about the previous study arms and their enrollment status have been removed.SummaryDifference21%
- Check54 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check61 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check90 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to Pembrolizumab Combo vs Alone in Stage III Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo vs Alone in Stage III Melanoma Clinical Trial page.